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HAAH is a protein that is over-expressed in cancer cells
and is presented on the surface of the cells and in the
growth zone of the tumors. It plays a central role in the
etiology of cancer, namely, in proliferation, motility and
invasion. It is, however, an embryonic protein important
during development and, as such, is a self protein to
which the immune system is tolerized. We are targeting
HAAH to develop an immunotherapy for cancer. To over-
come the self-antigen tolerance of the molecule, we have
designed a vaccine entity that contains an immunostimu-
lant and presents HAAH in a manner that is unfamiliar to
the body. We have expressed three portions of the HAAH
protein, sequences from the N-terminus, middle portion
and C-terminus, as fusion proteins (with the gpD bacter-
iophage antigen) on the surface of bacteriophage lambda,
generating 200-300 copies per phage. These vaccine enti-
ties have been characterized and are readily and routinely
produced at a level of 1012 plaque-forming units (pfu) per
liter of E. coli culture. The bacteriophage vaccines have
been successfully isolated and purified using tangential
flow filtration, a highly scalable process, as well as by PEG
precipitation followed by exhaustive dialysis. Both of these
processes have reduced bacterial endotoxins to levels
within FDA guidelines for formulated human doses. The
ease and yield of the manufacturing process allow produc-
tion of approximately 1000 human doses (based on our
anticipated dose requirement for immunogenicity in
human subjects) per liter of culture. The bacteriophage
can be rendered noninfectious by ultraviolet irradiation;
hence referred to as nano-particle-based vaccine. We have
demonstrated in previous passive immunotherapy studies
that monoclonal antibodies to HAAH inhibit in vitro
tumor cell growth, motility and invasiveness and inhibit in
vivo tumor growth in mouse xenograft models of cancer.
Building on these results, we are using the therapeutic
cancer vaccine described here to overcome the self-
tolerance to HAAH by the presentation of the altered
HAAH antigen (the fusion proteins using HAAH frag-
ments) on a solid phase and the immunomodulatory effect
of the bacteriophage itself in recruiting dendritic cells to
this antigen. This vaccine should therefore produce a
strong polyclonal antibody response and a cellular
immune response that will result in enhanced inhibition
of tumor cell function and efficacy as an anti-cancer
immunotherapeutic agent.
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